Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival

被引:73
作者
Cawthorn, Thomas R. [1 ,5 ]
Moreno, Juan C. [1 ,2 ]
Dharsee, Moyez [3 ]
Danh Tran-Thanh [1 ,2 ]
Ackloo, Suzanne [3 ]
Zhu, Pei Hong [3 ]
Sardana, Girish [3 ]
Chen, Jian [3 ]
Kupchak, Peter [3 ]
Jacks, Lindsay M. [4 ]
Miller, Naomi A. [2 ,6 ]
Youngson, Bruce J. [2 ,6 ]
Iakovlev, Vladimir [6 ,7 ]
Guidos, Cynthia J. [8 ,9 ]
Vallis, Katherine A. [10 ]
Evans, Kenneth R. [3 ]
McCready, David [11 ]
Leong, Wey L. [11 ]
Done, Susan J. [1 ,2 ,5 ,6 ]
机构
[1] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada
[2] Univ Hlth Network, Lab Med Program, Toronto, ON, Canada
[3] Ontario Canc Biomarker Network, Toronto, ON, Canada
[4] Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada
[6] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[7] St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada
[8] Univ Toronto, Hosp Sick Children, Res Inst, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada
[9] Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada
[10] Univ Oxford, MRC CRUK Gray Inst Radiat Oncol & Biol, Oxford, England
[11] Univ Hlth Network, Dept Surg Oncol, Toronto, ON, Canada
来源
PLOS ONE | 2012年 / 7卷 / 02期
基金
加拿大健康研究院;
关键词
TUMOR-MARKERS CA-15-3; B-RAF; PROTEIN; MODULATION; RECEPTOR; ACTIVATION; INDUCTION; APOPTOSIS; SEQUENCE; ISOFORMS;
D O I
10.1371/journal.pone.0030992
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality. About 10% of North American women will be diagnosed with breast cancer during their lifetime and 20% of those will die of the disease. Breast cancer is a heterogeneous disease and biomarkers able to correctly classify patients into prognostic groups are needed to better tailor treatment options and improve outcomes. One powerful method used for biomarker discovery is sample screening with mass spectrometry, as it allows direct comparison of protein expression between normal and pathological states. The purpose of this study was to use a systematic and objective method to identify biomarkers with possible prognostic value in breast cancer patients, particularly in identifying cases most likely to have lymph node metastasis and to validate their prognostic ability using breast cancer tissue microarrays. Methods and Findings: Differential proteomic analyses were employed to identify candidate biomarkers in primary breast cancer patients. These analyses identified decorin (DCN) and endoplasmin (HSP90B1) which play important roles regulating the tumour microenvironment and in pathways related to tumorigenesis. This study indicates that high expression of Decorin is associated with lymph node metastasis (p < 0.001), higher number of positive lymph nodes (p < 0.0001) and worse overall survival (p = 0.01). High expression of HSP90B1 is associated with distant metastasis (p < 0.0001) and decreased overall survival (p < 0.0001) these patients also appear to benefit significantly from hormonal treatment. Conclusions: Using quantitative proteomic profiling of primary breast cancers, two new promising prognostic and predictive markers were found to identify patients with worse survival. In addition HSP90B1 appears to identify a group of patients with distant metastasis with otherwise good prognostic features.
引用
收藏
页数:11
相关论文
共 42 条
[1]   Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment [J].
Bartsch, R ;
Wenzel, C ;
Pluschnig, U ;
Hussian, D ;
Sevelda, U ;
Altorjai, G ;
Locker, GJ ;
Mader, R ;
Zielinski, CC ;
Steger, GG .
BMC CANCER, 2006, 6 (1)
[2]   Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases [J].
Becker, B ;
Multhoff, G ;
Farkas, B ;
Wild, PJ ;
Landthaler, M ;
Stolz, W ;
Vogt, T .
EXPERIMENTAL DERMATOLOGY, 2004, 13 (01) :27-32
[3]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[4]  
2-H
[5]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[6]   Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy [J].
Cox, C ;
White, L ;
Allred, N ;
Meyers, M ;
Dickson, D ;
Dupont, E ;
Cantor, A ;
Ly, Q ;
Dessureault, S ;
King, J ;
Nicosia, S ;
Vrcel, V ;
Diaz, N .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (05) :708-711
[7]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540
[8]   Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin [J].
Dias, SD ;
Friedlos, F ;
Light, Y ;
Springer, C ;
Workman, P ;
Marais, R .
CANCER RESEARCH, 2005, 65 (23) :10686-10691
[9]   Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling [J].
Feugaing, David Denis Sofeu ;
Tammi, Raija ;
Echtermeyer, Frank G. ;
Stenmark, Harald ;
Kresse, Hans ;
Smollich, Martin ;
Schoenherr, Elke ;
Kiesel, Ludwig ;
Goette, Martin .
BIOCHIMIE, 2007, 89 (05) :637-657
[10]   Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of α2β1 integrin activity [J].
Fiedler, Lorna R. ;
Schoenherr, Elke ;
Waddington, Rachel ;
Niland, Stephan ;
Seidler, Daniela G. ;
Aeschlimann, Daniel ;
Eble, Johannes A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (25) :17406-17415